Marco Zarbin, MD
Ophthalmology · Newark, NJNPI 1376641423
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $47,597 of the $52,077 with a category attached, or 91.4%. 8 manufacturers reported payments, led by Apellis Pharmaceuticals, Inc. at 26.6% of the total. Reporting peaked in 2021 at $12,320 and has fallen 52.1% since, to $5,900 in 2025. Among ophthalmology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 20 payments — averaging $2603.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apellis Pharmaceuticals, Inc.$14K
- Genentech, Inc.$13K
- Novartis$10K
- Novartis Pharma AG$5K
- AbbVie$4K
- F. Hoffmann-la Roche AG$3K
- plus $3K from 2 others
Across 18 payments — averaging $2626.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- F. Hoffmann-la Roche AG$30K
- Novartis$13K
- Novartis Pharma AG$4K
What the payments were for
- Consulting fees$47,59791%
- Speaking & faculty fees$3,4457%
- Travel & lodging$9752%
- Food & beverage$600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | 4 | $13,847 |
| Genentech, Inc. | 8 | $12,645 |
| Novartis | 2 | $9,995 |
| Novartis Pharma AG | 1 | $5,375 |
| AbbVie | 1 | $4,271 |
| F. Hoffmann-la Roche AG | 2 | $2,945 |
| Iridex Corporation | 1 | $2,000 |
| Boehringer Ingelheim International GmbH | 1 | $1,000 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,077 in reported general payments places this provider in the 95th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ketorolac Tromethamine | 108 | $4,438 |
| Prednisolone Acetate | 102 | $4,049 |
| Brimonidine Tartrate | 34 | $1,520 |
| Atropine Sulfate | 20 | $643 |
| Acetazolamide | 11 | $365 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 32 | $352 |
| Latanoprost | 12 | $49 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Newark
- Albert KhouriNewark$428K
- Robert FechtnerNewark$324K
- Jai ParekhWoodland Park$2M
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Cynthia MatossianPennington$655K
- Eric MannDover$604K
- Brett BieloryRutherford$477K
- Rajen DesaiFreehold$311K
- Douglas GraysonIselin$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.